Search | Clinical Trials Finder

Conditions: Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Cancer, Metastatic Pancreatic Cancer
Interventions: M7824, M9241, SBRT; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer Stage IV
Interventions: Blood and tumor tissue analysis, Clinical response.; Other
Lead sponsor: Holy Cross Hospital, Maryland; Other
Eligibility: 18 Years to 70 Years
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Melanoma
Interventions: Infliximab, Vedolizumab; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gastroesophageal Cancer, Immune Checkpoint Inhibition
Interventions: Nivolumab, Relatlimab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 99 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: Baltimore, Maryland • Pittsburgh, Pennsylvania • Dallas, Texas

Conditions: Transitional Cell Carcinoma
Interventions: Pembrolizumab and Ramucirumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma, Node-positive Breast Cancer
Interventions: Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost; Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions: INCB001158, Pembrolizumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 13
States / cities: Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more

Conditions: Immune-related Colitis, Colitis
Interventions: RMT, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Brainerd, Minnesota • Deer River, Minnesota • Detroit Lakes, Minnesota + 6 more

Conditions: Renal Cell Carcinoma
Interventions: Tivozanib, Nivolumab; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 36
States / cities: Duarte, California • Irvine, California • La Jolla, California + 31 more

Conditions: Metastatic Melanoma, Liver Metastases
Interventions: Nivolumab and Relatlimab, Melphalan; Drug · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Melanoma, Uveal
Interventions: Pembrolizumab, Lenvatinib; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions: azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Malignancy
Interventions: One or more off-label ICIs alone or with other on-label ICI(s), Off-label ICI(s) with targeted therapy, off-label ICI(s) with other agents that are not targeted (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy other than ICIs) with or without targeted agents; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Glioma, Malignant
Interventions: AdV-tk, Valacyclovir, Radiation, Temozolomide, Nivolumab, Laboratory Biomarker Analysis; Biological · Drug · Radiation + 1 more
Lead sponsor: Candel Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Boston, Massachusetts • Detroit, Michigan • Winston-Salem, North Carolina + 2 more

Conditions: Advanced Solid Tumor
Interventions: hSTC810; Biological
Lead sponsor: STCube, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: New Haven, Connecticut • New York, New York • Houston, Texas

Conditions: NSCLC Stage IV
Interventions: N-803, Tislelizumab, Docetaxel, Prior failed checkpoint inhibitor; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 19
States / cities: Springdale, Arkansas • El Segundo, California • Fountain Valley, California + 14 more

Conditions: Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Durvalumab, Lenalidomide, Rituximab, Ibrutinib, Bendamustine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 19
States / cities: Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more

Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Cancer Metastatic
Interventions: Nivolumab 480mg and surgical resection; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
Interventions: Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), Cryoablation; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer, Nonsmall Cell
Interventions: Blood and tissue samples; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Adult Solid Tumor
Interventions: SQZ-AAC-HPV, Ipilimumab, Nivolumab; Biological · Drug
Lead sponsor: SQZ Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: Duarte, California • La Jolla, California • Detroit, Michigan + 3 more

Conditions: Pancreatic Cancer
Interventions: MEDI4736, Tremelimumab, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • New York, New York • The Bronx, New York

Conditions: Malignant Skin Neoplasm, Melanoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer
Interventions: Dato-DXd, Durvalumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pembrolizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 66
States / cities: Daphne, Alabama • Springdale, Arkansas • Duarte, California + 57 more

Search by objective public record fields.

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

Personalizing Immune Checkpoint Inhibitor Therapy

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Off-Label Treatment With Immune Checkpoint Inhibitor Blockade

GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)